Terms: = Liver cancer AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Diagnosis
22 results:
1. Asymptomatic Essential Thrombocytosis Presenting with Extrahepatic Portal Vein Thrombosis: A Case Report.
Yakami Y; Yagyu T; Bando T; Hanada M
Am J Case Rep; 2023 Sep; 24():e938547. PubMed ID: 37766423
[TBL] [Abstract] [Full Text] [Related]
2. UBE2S promotes malignant properties via VHL/HIF-1α and VHL/jak2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma.
Wu J; Xu X; Wu S; Shi W; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
Cancer Med; 2023 Sep; 12(17):18078-18097. PubMed ID: 37563971
[TBL] [Abstract] [Full Text] [Related]
3. Acute graft-versus-host disease.
Malard F; Holler E; Sandmaier BM; Huang H; Mohty M
Nat Rev Dis Primers; 2023 Jun; 9(1):27. PubMed ID: 37291149
[TBL] [Abstract] [Full Text] [Related]
4. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
Faria C; Tzankov A
Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
[TBL] [Abstract] [Full Text] [Related]
5. Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma.
Jiang C; Liu Z; Yuan J; Wu Z; Kong L; Yang J; Lv T
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901767
[TBL] [Abstract] [Full Text] [Related]
6. The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.
Slot S; van de Donk NWCJ; Otten RHJ; Boden BJH; Zijlstra J; Raijmakers PGHM; Zweegman S
Cancer Imaging; 2021 Apr; 21(1):36. PubMed ID: 33879266
[TBL] [Abstract] [Full Text] [Related]
7. Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.
Kwiatkowski J; Kuliszkiewicz-Janus M; Rymer W; Jaźwiec B; Małecki R
Pharmacology; 2021; 106(5-6):316-322. PubMed ID: 33691325
[TBL] [Abstract] [Full Text] [Related]
8. Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma.
Gaia S; Ciruolo M; Ribaldone DG; Rolle E; Migliore E; Mosso E; Vola S; Risso A; Fagoonee S; Saracco GM; Carucci P
Curr Oncol; 2021 Feb; 28(2):1034-1044. PubMed ID: 33669107
[TBL] [Abstract] [Full Text] [Related]
9. Sclerosing Extramedullary Hematopoietic Tumor: A Case Report.
Wang D; Castro E; Rao A; McPhaul CM
J Investig Med High Impact Case Rep; 2020; 8():2324709620956463. PubMed ID: 32911987
[TBL] [Abstract] [Full Text] [Related]
10. Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses.
Debureaux PE; Cassinat B; Soret-Dulphy J; Mora B; Verger E; Maslah N; Plessier A; Rautou PE; Ollivier-Hourman I; De Ledinghen V; Goria O; Bureau C; Siracusa C; Valla D; Giraudier S; Passamonti F; Kiladjian JJ
Blood Adv; 2020 Aug; 4(15):3708-3715. PubMed ID: 32777065
[TBL] [Abstract] [Full Text] [Related]
11. Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
Magaz M; Alvarez-Larrán A; Colomer D; López-Guerra M; García-Criado MÁ; Mezzano G; Belmonte E; Olivas P; Soy G; Cervantes F; Darnell A; Ferrusquía-Acosta J; Baiges A; Turon F; Hernández-Gea V; García-Pagán JC
J Hepatol; 2021 Jan; 74(1):89-95. PubMed ID: 32679300
[TBL] [Abstract] [Full Text] [Related]
12. Review article: a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome.
Khan F; Armstrong MJ; Mehrzad H; Chen F; Neil D; Brown R; Cain O; Tripathi D
Aliment Pharmacol Ther; 2019 Apr; 49(7):840-863. PubMed ID: 30828850
[TBL] [Abstract] [Full Text] [Related]
13. LncRNA 00152 promotes the development of hepatocellular carcinoma by activating jak2/STAT3 pathway.
Li SJ; Sui MH; Sun ZX; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1038-1046. PubMed ID: 30779070
[TBL] [Abstract] [Full Text] [Related]
14. Budd-Chiari syndrome/hepatic venous outflow tract obstruction.
Valla DC
Hepatol Int; 2018 Feb; 12(Suppl 1):168-180. PubMed ID: 28685257
[TBL] [Abstract] [Full Text] [Related]
15. Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.
Andrici J; Farzin M; Clarkson A; Sioson L; Sheen A; Watson N; Toon CW; Koleth M; Stevenson W; Gill AJ
Pathology; 2016 Jun; 48(4):319-24. PubMed ID: 27114372
[TBL] [Abstract] [Full Text] [Related]
16. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.
De Stefano V; Qi X; Betti S; Rossi E
Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846
[TBL] [Abstract] [Full Text] [Related]
17. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
[TBL] [Abstract] [Full Text] [Related]
18. Risk Factors, diagnosis, Management, and Outcome of Splanchnic Vein Thrombosis: A Retrospective Analysis.
Derman BA; Kwaan HC
Semin Thromb Hemost; 2015 Jul; 41(5):503-13. PubMed ID: 26080303
[TBL] [Abstract] [Full Text] [Related]
19. Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis.
Turon F; Cervantes F; Colomer D; Baiges A; Hernández-Gea V; Garcia-Pagán JC
J Hepatol; 2015 Jan; 62(1):72-4. PubMed ID: 25173966
[TBL] [Abstract] [Full Text] [Related]
20. [Portal vein thrombosis as the main symptom of unclassified jak2-positive myeloproliferative neoplasm--case report].
Karakulska-Prystupiuk E; Gierej B; Paszkowska-Kowalewska M; Wilkowojska U; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Jul; 33(193):29-31. PubMed ID: 22993907
[TBL] [Abstract] [Full Text] [Related]
[Next]
